Stanford Advisors


All Publications


  • Overcoming EGFR Resistance by Monovalent and Bident Inhibitors Targeting Cys775. ACS central science Li, Z., Jiang, J., Wang, Y., Ficarro, S. B., Collins, S. J., Beyett, T. S., Schaeffner, I. K., Tavares, I., Gottlieb, F. H., Suda, D., Gokhale, P. C., Black-Holmes, L. M., Gazgalis, D., Eck, M. J., Jänne, P. A., Marto, J. A., Che, J., Gray, N. S., Zhang, T. 2026; 12 (10): 1647-1658

    Abstract

    Covalent targeting of EGFR cysteine 797 by osimertinib is one of the most successful breakthroughs in targeted therapy, fundamentally transforming the treatment landscape for non-small-cell lung cancer (NSCLC) patients. However, resistance driven by the mutation of C797 remains a major clinical challenge. Developing novel covalent strategies beyond C797 targeting presents a compelling opportunity for next-generation EGFR inhibitors. We first demonstrated that cysteine 775, located deep within the ATP-binding pocket, is accessible by a rationally designed covalent molecule ZNL-3, which as the first-in-class covalent cysteine 775 inhibitor exhibited strong efficacy in osimertinib-resistant mouse models. To further enhance resilience to resistance-causing mutations, we developed a dual-warhead, bident compound YNW-1 which covalently targets both cysteines 775 and 797 simultaneously. YNW-1 is the first intramolecular lock to exhibit balanced reactive efficiency on both cysteines, rendering single-site mutations ineffective at conferring resistance. This study establishes the therapeutic potential of an EGFR covalent inhibitor through unprecedented targeting of cysteine 775. It also provides the first evidence that dual-cysteine engagement offers superior efficacy to conventional covalent inhibitors by delaying the emergence of resistance. Further optimization for clinical translation is currently ongoing in our laboratory.

    View details for DOI 10.1021/acscentsci.6c01219

    View details for PubMedID 42964983

    View details for PubMedCentralID PMC13720926

  • Overcoming EGFR Resistance by Monovalent and Bident Inhibitors Targeting Cys775 ACS CENTRAL SCIENCE Li, Z., Jiang, J., Wang, Y., Ficarro, S. B., Collins, S. J., Beyett, T. S., Schaeffner, I. K., Tavares, I., Gottlieb, F. H., Suda, D., Gokhale, P. C., Black-Holmes, L. M., Gazgalis, D., Eck, M. J., Janne, P. A., Marto, J. A., Che, J., Gray, N. S., Zhang, T. 2026
  • Targeting EGFR cysteine 775 in EGFR mutant lung cancer Jiang, J., Li, Z., Wang, Y., Collins, S. J., Gottlieb, F. H., Gokhale, P. C., Eck, M. J., Janne, P. A., Che, J., Gray, N. S., Zhang, T. AMER ASSOC CANCER RESEARCH. 2026
  • An AKR1C3-activated kinase inhibitor prodrug. RSC chemical biology Li, Z., Martinez, M., Byun, W. S., Thathireddy, A., Qiu, T., Wang, Y., Katzengruber, L., Chouldjian, A., Lu, W., Ji, W., Che, J., Zhang, T., Hinshaw, S. M., Gray, N. S. 2025

    Abstract

    Enzymatically activated prodrugs can enable context-specific target inhibition. AKR1C3 is an NADPH-dependent aldo-ketoreductase involved in androgen metabolism, prostaglandin synthesis, and cell proliferation that is overexpressed in tumors, making it an ideal candidate for tumor-specific prodrug activation. Reported prodrugs that exploit AKR1C3 catalytic activity release DNA-intercalating toxins or other non-selective poisons upon enzymatic activation. OBI-3424, a prodrug of a DNA alkylating agent, is a prominent example of this strategy. To extend this concept to selective enzymatic inhibitors, we have developed AKR1C3-activated prodrugs of OTS964, a CDK11 inhibitor. We have probed the activities of the compounds with biochemical and cellular assays, finding specific activation of the lead prodrug by AKR1C3. Upon enzymatic conversion, the compound recapitulates the cellular activity of the parent compound. These results demonstrate that the AKR1C3-activated prodrug strategy can be used to convert selective kinase inhibitors into context-dependent prodrugs. Extension of this approach may enable synthesis of prodrugs for targeted therapies that spare normal tissue, further improving their therapeutic windows.

    View details for DOI 10.1039/d5cb00219b

    View details for PubMedID 41488912

    View details for PubMedCentralID PMC12757751

  • Overcoming EGFR resistance by monovalent and bident inhibitors targeting Cys775. bioRxiv : the preprint server for biology Li, Z., Jiang, J., Wang, Y., Ficarro, S. B., Collins, S. J., Beyett, T. S., Schaeffner, I. K., Tavares, I., Gottlieb, F. H., Suda, D., Gokhale, P. C., Black-Holmes, L. M., Gazgalis, D., Eck, M. J., Jänne, P. A., Marto, J. A., Che, J., Gray, N. S., Zhang, T. 2025

    Abstract

    Covalent targeting of EGFR cysteine 797 by osimertinib is one of the most successful breakthroughs in targeted therapy, fundamentally transforming the treatment landscape for non-small cell lung cancer (NSCLC) patients. However, resistance driven by mutation of C797 remains a major clinical challenge. Developing novel covalent strategies beyond C797 targeting presents a compelling opportunity for next-generation EGFR inhibitors. We first demonstrated that cysteine 775, located deep within the ATP-binding pocket, is accessible by a rationally designed covalent molecule ZNL-3, which as the first-in-class covalent cysteine 775 inhibitor exhibited strong efficacy in osimertinib-resistant mouse models. To further enhance resilience to resistance-causing mutations, we developed a dual-warhead, bident compound-YNW-1-which covalently targets both cysteine 775 and 797 simultaneously. YNW-1 is the first intramolecular lock to exhibit balanced reactive efficiency on both cysteines, rendering single-site mutations ineffective to confer resistance. The discovery of ZNL-3 and YNW-1 represents significant advancements in EGFR-targeted drug development, and further optimization toward clinical translation is a worthwhile strategy.

    View details for DOI 10.64898/2025.11.28.691243

    View details for PubMedID 41573874

    View details for PubMedCentralID PMC12822668

  • New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. Cell chemical biology Arwood, M. L., Liu, Y., Harkins, S. K., Weinstock, D. M., Yang, L., Stevenson, K. E., Plana, O. D., Dong, J., Cirka, H., Jones, K. L., Virtanen, A. T., Gupta, D. G., Ceas, A., Lawney, B., Yoda, A., Leahy, C., Hao, M., He, Z., Choi, H. G., Wang, Y., Silvennoinen, O., Hubbard, S. R., Zhang, T., Gray, N. S., Li, L. S. 2023

    Abstract

    Recurrent JAK2 alterations are observed in myeloproliferative neoplasms, B-cell acute lymphoblastic leukemia, and other hematologic malignancies. Currently available type I JAK2 inhibitors have limited activity in these diseases. Preclinical data support the improved efficacy of type II JAK2 inhibitors, which lock the kinase in the inactive conformation. By screening small molecule libraries, we identified a lead compound with JAK2 selectivity. We highlight analogs with on-target biochemical and cellular activity and demonstrate in vivo activity using a mouse model of polycythemia vera. We present a co-crystal structure that confirms the type II binding mode of our compounds with the "DFG-out" conformation of the JAK2 activation loop. Finally, we identify a JAK2 G993A mutation that confers resistance to the type II JAK2 inhibitor CHZ868 but not to our analogs. These data provide a template for identifying novel type II kinase inhibitors and inform further development of agents targeting JAK2 that overcome resistance.

    View details for DOI 10.1016/j.chembiol.2023.05.007

    View details for PubMedID 37290440